There are pharmaceutical companies that can fit into a value investor's portfolio. Broadly speaking, these companies look ...

Bristol-Myers Squibb (BMY) is back in focus after releasing positive Phase 3 data for Camzyos in adolescents with obstructive ...

Oxford BioTherapeutics has entered a multi‑year collaboration with Bristol Myers Squibb to discover and develop novel T‑cell ...

Bristol Myers Squibb (NYSE:BMY) announced a new multi year cancer immunotherapy partnership with Oxford BioTherapeutics. The ...

Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to ...

The past five years have been challenging for Bristol Myers Squibb (NYSE: BMY). The company lost patent exclusivity for some key products, including one that was once its best-selling medicine, cancer ...

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, ...

Bristol-Myers Squibb Co. and three subsidiaries of Sanofi are likely to get to defend Medicaid fraud claims from Texas ...

Bristol Myers Squibb is adding three prescription medications on TrumpRx.gov on Monday, offering discounts of up to 90%, FOX ...

Deep-pocketed investors have adopted a bullish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) announced today the launch of "Change the Target. Change What’s Possible." an educational campaign developed in partnership with ...